Use of mycophenolate mofetil (MMF), a novel immunosuppressant that inhibits T-and B-cell proliferation, together with a calcineurin inhibitor (CNI) has recently increased in cord blood transplantation (CBT) to reduce severe GVHD and pre-engraftment syndrome (PES). 1, 2 Wide interpatient variability has been reported in the plasma levels of mycophenolate (MPA), an active form of MMF, even after the same MMF exposure; however, few reports have performed therapeutic drug monitoring in CBT. 3 Therefore, we performed a prospective cohort study to (1) determine the correlation between MPA concentration and incidence of severe PES or acute GVHD (aGVHD) after CBT and (2) compare the incidence of these complications with the historical cohort using CNI alone for GVHD prophylaxis after CBT.
We continuously enrolled 24 adult patients who underwent single-unit CBT with GVHD prophylaxis using CNI and MMF at our department between September 2011 and December 2013. The protocols were approved by the Ethics Committee of Kyoto University. The historical cohort consisted of 38 patients who received single-unit CBT with GVHD prophylaxis using CNI alone between June 2003 and August 2011. Patient characteristics and CBT procedures are summarized in Table 1 , and definition of transplantation risk and myeloablative conditioning regimens were in accordance with previous studies. 4, 5 MMF was orally administered at 10 mg/kg, three times a day (i.e. total dose=30 mg/kg/day) (with the exact intervals of 8 h), from Day 0 to Day 30. The MMF dosage was not modified during the clinical course after CBT. PES was defined as noninfectious fever with an unexplained skin rash before neutrophil engraftment. 6 Severe PES was defined according to a previous report. 2 Blood samples were collected immediately before and 1, 2 and 4 h after the morning administration of MMF on Day 7 (first week) and Day 21 (third week) after CBT. Total MPA levels in the plasma were measured using the enzyme multiplied immunoassay technique (EMIT) 7 (C 0 , C 1 , C 2 and C 4 , respectively), and C 8 (which means the trough level of the next administration) was assumed to be equal to C 0 values based on results of our preliminary analysis (n = 12 both at the first and third weeks) and other studies. 3, 8, 9 Area under the curve (AUC) 0-8 h was determined using the linear trapezoidal method, and the AUC 0-24 h was calculated as 3 × AUC 0-8 h . This method is one of the standards in the setting of MMF administration three times a day (every 8 h), 3, 8 because MPA concentrations reached to the peak within 2 h from administration, and decreased linearly after 4 h. 9 Patients whose AUC 0-24 h was below the lower quartile were categorized in 'the lower concentration group' at each time point (first and third week). We set our threshold at the lower quartile in order to find out the minimally required concentration of MPA AUC 0-24 h to prevent PES and aGVHD effectively.
Cumulative incidence of PES and aGVHD was calculated in each cohort using Gray's method, and relapse or early death was considered a competing risk. Statistical analyses were performed using R (The R Foundation for Statistical Computing, version 2.13.0). The alpha level of all the tests and the P-value were set at 0.05.
MPA measurements revealed that C 1 showed the highest values among the four points (mean ± s.d. in the first and third week; C 0 , 0.92 ± 0.87 and 0.92 ± 0.84 μg/mL; C 1 , 5.96 ± 3.88 and 5.47 ± 4.11 μg/mL; C 2 , 4.18 ± 1.87 and 3.63 ± 1.99 μg/mL; and C 4 , 1.56 ± 0.81 and 1.52 ± 0.97 μg/mL). The AUC 0-24 h was 54.3 ± 21.9 μg h/mL (mean ± s.d.) in the first week and 50.0 ± 22.2 μg h/mL in the third week. The threshold of lower or higher MPA AUC 0-24 h levels was set at 40 μg h/mL in both the first and third weeks, because the lower quartile values were 38.7 and 35.6 μg h/mL, respectively.
As per results, severe PES was observed in two patients, whose AUC 0-24 h in the first week was 23.0 μg h/mL (the lowest in the MMF cohort) and 84.0 μg h/mL (the third highest), indicating that severe PES may occur regardless of the MPA concentration. Actually, there was no statistical difference in the incidence of severe PES between the two groups in the first week (lower vs higher concentration groups; n = 7 vs n = 17; incidence 14.3% vs 5.9%, P = 0.53, respectively). The incidence of severe PES for the entire MMF group (8.3%) was significantly lower than that of the historical control cohort (CNI alone; 31.6%, P = 0.02) (Figure 1a) . On the other hand, the incidence of aGVHD (grade 2-4) was significantly higher in the lower concentration group (n = 8) compared with the higher cohort in the third week (n = 16; 75.0% vs 31.2% on Day 100, P = 0.02; Figure 1b) . This difference was still significant after adjusting for various confounding factors between the two groups (age, transplantation risk, conditioning regimens, donor-recipient sex and ABO mismatch and prior severe PES), and the relative risk was 8.05 (95% confidence interval 1.09-59.7, P = 0.04). The incidence of aGVHD in the whole MMF group (45.8%) was similar to the historical cohort (39.5%, P = 0.72; Figure 1c ).
The relapse rate was unrelated to the MPA concentration (the higher AUC group, 22.8%; the lower group, 16.7% at 1 year; P = 0.76), and that rate was almost the same both in the entire MMF group and in the historical cohort (MMF group, 20.6%; historical cohort, 28.6% at 1 year, P = 0.54). As for infection, the incidence of severe bacterial infection (documented bacteremia up to Day 100) was 25.0% in the MMF group, similar to that in the historical cohort (31.6%, P = 0.62). The incidence of human herpes virus (HHV)-6 reactivation was higher in the MMF group (53.6% at Day 100) than in the historical cohort (34.2%, P = 0.15). There was no increase in the incidence of other viral or fungal infections.
In the present prospective cohort study, we demonstrated that (1) a certain level of MPA is necessary to effectively prevent aGVHD after CBT and (2) severe PES can be reduced with the addition of MMF to CNI as GVHD prophylaxis. First, we observed that MPA levels and the AUC 0-24 h widely fluctuated among patients and time points after CBT because the kinetics of MMF are drastically influenced by gastrointestinal damages caused by preparative regimens, loss of appetite and decreased oral intake or other drug interactions. 10 However, appropriate concentrations are still not confirmed in patients who undergo CBT. 1 We suggest that an AUC 0-24 h of 40 μg h/mL in the third week should be the minimal requirement. In contrast, another group calculated AUC 0-24 h just as the same strategy with ours, and reported that even AUC 0-24 h o30 μg h/mL was sufficient to decrease the incidence of aGVHD in a small cohort study. 3 Their patient characteristics, transplant procedures and strategies of MMF administration and AUC calculation were almost the same as those used for our patients. Therefore, these controversial data should be validated in large-scale prospective studies.
Next, we demonstrated that even lower concentrations of MMF could reduce the incidence of severe PES compared with CNI alone. Severe PES may increase the risk of infection and organ dysfunction, leading to high rates of TRM.
2 A previous study demonstrating that CBT after reduced-intensity conditioning regimens decreased the incidence of severe PES with GVHD prophylaxis using MMF plus CNI compared with CNI alone support our results. 2 An increase in relapse was not shown in the MMF cohort, and the infection rate was almost the same except for HHV-6 reactivation. These data suggest that GVHD prophylaxis using MMF and CNI may be a more advantageous strategy compared with CNI alone.
In summary, drug monitoring of MMF is necessary for the effective prophylaxis of aGVHD after CBT. This study has the limitation of a small patient number, so large-scale prospective studies are needed to substantiate our results and to determine the optimal GVHD prophylaxis regimen. Moreover, measuring the levels of the unbound form of MPA 11 or the activity of inosine monophosphate dehydrogenase isoenzymes 12 may be necessary to analyze the direct effects of MMF on lymphocytes after CBT. Abbreviations: CNI = calcineurin inhibitor; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; N = no; NCC = nuclear cell count; RIC = reducedintensity conditioning; Y = yes. The lower concentration group had a significantly higher incidence of aGVHD than the higher group (P = 0.02). (c) The incidence was the same in the historical cohort (CNI alone) and the entire MMF group (P = 0.72).
